Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Teva
Israel - Petach Tikva
METOPROLOL SUCCINATE (metoprolol succinate) by Teva is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure, the long-term treatment of angina pectoris and 5 more indications. First approved in 2018.
Drug data last refreshed 18h ago
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Worked on METOPROLOL SUCCINATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition
Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo